The Next Wave of Testing Heart Arrhythmia Drugs
Testing new drugs is no easy task. Animal testing may show successful results that aren't replicated in humans, and having drug trials in individuals could result in undesirable side effects.
Preventing Strokes in Arrhythmia Patients
Atrial fibrillation, a common heart arrhythmia, is generally treated with a standard drug warfarin. However, a study suggests a new drug might provide the same treatment, but with a lower risk of stroke and embolism.
Obesity Linked to Heart Arrhythmia
With obesity comes the added risk of health problems. One potential risk may be electrical heart abnormalities that can lead to heart arrhythmia.
Alternative Drug Better Treats Heart Arrhythmia
A medication considered the standard for preventing stroke in heart arrhythmia patients may not be as effective as an anti-clotting drug that also boasts fewer side effects.
Heart Beat Raises Dementia Risk
Irregular heartbeat isn't usually life-threatening. It is relatively easy to manage. However, those with the disorder may be at a heightened risk for developing dementia, including Alzheimer's disease.
Atrial Fibrillation Rx Alert
Last month the PALLAS trial revealed adverse cardiovascular risks in taking dronedarone (Multaq) for irregular heart beat. Now the European Society of Cardiology is suggesting its use be limited.
Light Controlled Heart Pacemakers
Just recently heart pacemakers went wireless. Now there is potential to take them even a step further. In the future they could be light-controlled.
Genetic Regulation Linked to Heart Arrhythmia
An irregular heart beat could be caused by a wide range of factors -- from scarring after a heart attack to diabetes and high blood pressure. New research also suggests a genetic link.
FDA Drug Safety Communication: Pradaxa
The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa ( dabigatran etexilate mesylate ) capsules.
(UPDATE 12/19) FDA Drug Safety Communication: Multaq (dronedarone)
The U.S. Food and Drug Administration (FDA) is reviewing data from a clinical trial that was evaluating the effects of the antiarrhythmic drug Multaq ( dronedarone ) in patients with permanent atrial fibrillation.